GMR Solutions Inc. 8-K

What Happened
GMR Solutions Inc. announced that Dr. Amar Desai and Ellen Zane were appointed to its Board of Directors effective July 1, 2026. The Board determined both directors are independent under NYSE rules. Ms. Zane will serve as a Class II director through the 2028 annual meeting; Dr. Desai will serve as a Class III director through the 2029 annual meeting.

Key Details

• Each new director received 9,972 restricted stock units (RSUs) under the 2026 Equity Incentive Plan; RSUs vest on the first anniversary of appointment or earlier upon a Change in Control or termination due to death or disability.
• Committee roles: Dr. Desai joins the Nominating, Corporate Governance and Compliance Committee; Ms. Zane will chair the Human Capital and Compensation Committee.
• Backgrounds: Dr. Desai most recently served as President of Optum Integrated Care (Aug 2025–Mar 2026) and CEO of Optum Health (Jul 2023–Aug 2025); Ms. Zane is CEO Emeritus of Tufts Medical Center and a current director at Boston Scientific, Haemonetics and Synchrony Financial.
• The company furnished a press release dated July 8, 2026 announcing the appointments (Exhibit 99.1). The filing reports no arrangements or related-party transactions requiring disclosure.

Why It Matters
These board additions bring senior health‑care and hospital system leadership to GMR Solutions, which may strengthen the company’s governance and industry expertise. The RSU awards align the new directors’ financial incentives with shareholders, and their committee assignments assign them to oversight and compensation roles that can influence corporate governance and executive pay policies. The classified board terms mean these seats are not up for reelection until 2028 and 2029, respectively.